title: Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
abstract: OBJECTIVE
  Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  Sixty eyes.
  
  
  METHODS
  Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed.
  
  
  RESULTS
  Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 µm (range 80-687 µm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 µm (-14%, range 34-701 µm), 215 µm (-18%, range 0-666 µm), and 208 µm (-22%, range 0-752 µm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R(2) = 0.11).
  
  
  CONCLUSIONS
  Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.
authors.affiliation: Retina Consultants of Houston, Weill Cornell Medical College, Houston Methodist Hospital.
authors.forename: James C
authors.initials: JC
authors.lastname: Major
authors.affiliation: Retina Consultants of Houston, Weill Cornell Medical College, Houston Methodist Hospital. Electronic address: ccwmd@houstonretina.com.
authors.forename: Charles C
authors.initials: CC
authors.lastname: Wykoff
authors.affiliation: Retina Consultants of Houston, Houston, Tex.
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Croft
authors.affiliation: Retina Consultants of Houston, Houston, Tex.
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.affiliation: Retina Consultants of Houston, Houston, Tex.
authors.forename: Angeline F
authors.initials: AF
authors.lastname: Mariani
authors.affiliation: Retina Consultants of Houston, Houston, Tex.
authors.forename: Anna E
authors.initials: AE
authors.lastname: Lehmann
authors.affiliation: Retina Consultants of Houston, Weill Cornell Medical College, Houston Methodist Hospital.
authors.forename: David M
authors.initials: DM
authors.lastname: Brown
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D057915:Drug Substitution; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D055213:Retinal Pigment Epithelium / Q000187:drug effects* / Q000473:pathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab